| IPO Company Profile |
| Current Quote | News | SEC Filings | Peer IPO Companies |
| Ophidian Pharmaceuticals, Inc. |
| 5445 East Cheryl Parkway, Madison, WI 53711 * (608) 271-0878 |
| The company is engaged in the research and development of pharmaceuticals with an emphasis on products for infectious diseases. The company is developing a product for the treatment of Clostridium difficile-associated disease. |
| Manager | Tier | Phone |
| Dirks & Company, Inc. | Lead Manager | |
| Security Capital Trading Corp. | Co-manager |
| AMEX: | OPHD | Service: | SIC 8731 | |
| Type of Shares: | Common Shares | Filing Date: | 8/8/97 | |
| U.S. Shares: | 1,750,000 | Offer Date: | 5/6/98 | |
| Non-U.S. Shares: | 0 | Filing Price: | $6.00 | |
| Primary Shares: | 1,750,000 | Offer Price: | $6.10 | |
| Secondary Shares: | 0 | Gross Spread: | $0.55 | |
| Offering Amount: | $10,500,000 | Selling: | $0.32 | |
| Expenses: | $350,000 | Reallowance: | $0.10 | |
| Post-IPO Shares: | 9,785,000 | |||
| Employees: | 29 |
| Issuer's Law Firm: | Lafollette & Sinykin |
| Bank's Law Firm: | Orrick, Herrington & Sutcliffe |
| Registrar/Transfer Agent: | Continental Stock Transfer & Trust Co |
| Auditor: | Ernst & Young |
Dollar amounts in U.S. millions except for per share data | |||||
| 9 Month Ending Financials | |||||
| Full Year Audited Income | Latest Unaudited Income | Prior Audited Income | Balance Sheet | ||
| 9/30/96 | 6/30/97 | 6/30/96 | 6/30/97 | ||
| Revenue: | $0.32 | $0.78 | $0.24 | Assets: | $6.89 |
| Net Income: | -$2.00 | -$1.54 | -$1.32 | Curr Assets: | $5.39 |
| EPS: | -$0.27 | -$0.21 | -$0.18 | Liabilities: | $13.23 |
| Prior EPS: | -$0.22 | Curr Liab: | $0.51 | ||
| Cash Flow/Oper: | -$1.58 | -$1.60 | -$1.00 | Equity: | -$6.34 |
| Cash Flow/Fin: | $3.51 | $3.01 | $0.99 | Cash: | $4.68 |
| Cash Flow/Inv: | $0.46 | -$0.01 | -$0.30 | Working Cap: | $4.88 |
| Competition |
| There are many companies, including the well-known pharmaceutical companies such as SmithKline Beecham Corporation, Bristol-Meyers Squibb Company, Abbott Laboratories and other smaller biotechnology firms, as well as academic and other research institutions, that are engaged in the discovery, development, marketing and sale of products for the treatment of infectious diseases. The Company expects to encounter significant competition for its product candidates from traditional and new treatment methods. Most of the Company's competitors and potential competitors have substantially greater capital, research and development capabilities and human resources than the Company. Furthermore, many of these competitors have significantly greater experience than the Company in undertaking pre-clinical testing and clinical trials of new biotechnology products and obtaining FDA and other regulatory approvals. If the Company is permitted to commence commercial sales of any product, it will also be competing with companies that have greater resources and experience in manufacturing, marketing and sales. The Company's competitors may succeed in developing products that are more effective, less costly, or have a better side effect profile than any that may be developed by the Company, and such competitors may also prove to be more successful than the Company in manufacturing, marketing and sales. If the Company is able to successfully commercialize a product, subsequent competitive developments could render such product noncompetitive or obsolete. |
| Business Plan |
| The company's strategy is to commercialize technologies and products from its research and development programs. The company intends to manufacture and sell its bulk pharmaceuticals, receive royalties from the sale of its product through marketing partners, receive license fees from the use of its technologies and establish sponsored research agreements encompassing company technologies. The company intends to achieve its objectives as follows: (I) Develop portfolio of infectious disease drugs, (ii) Develop new technologies for drug discovery and formulation, (iii) Develop business and enhance research through collaborations and (iv) Establish manufacturing capability to facilitate new product development and retain a greater portion of product value. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used for technology development, new product discovery and development, capital expenditures and working capital. |
| Name of Shareholder | % Owned Before | % Owned After |
| Dr. Margaret B. van Boldrik | 0.22 | 0.16 |
| Dr. Sean B. Carroll | 0.21 | 0.16 |
| Mr. William A. Linton | 0.10 | 0.07 |
| Eli Lilly and Company | 0.10 | 0.07 |
| Officer Name | Title | Age |
| Mr. William A. Linton | Chairman of the Board, Director | 50 |
| Dr. Margaret B. van Boldrik | Director, Vice President, Secretary | 41 |
| Dr. Douglas C. Stafford | President, Chief Executive Officer, Director, Treasurer | 41 |
| Dr. F. Michael Hoffmann | Vice President, Genetic Technology Programs | 46 |
| Dr. Joseph R. Firca | Vice President, Research and Development | 52 |
| Additional Underwriter Compensation |
| Warrant to purchase 250,000 shares/units at $25.00 per share/unit. |
| Exercise price of $7.20 for 4 year(s), 1 year(s) from 5/6/98. |